Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PLX8394 × 1 year × Clear all
NCT05503797 2026-06-05

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Fore Biotherapeutics

Phase 2 Recruiting
254 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡